What were Intelence (etravirine) 2023 sales, and who reported them?
I don’t have enough provided information to state Intelence 2023 sales or to attribute those numbers specifically to Janssen.
Intelence (etravirine) is an HIV medicine marketed by Janssen in many regions, but the exact 2023 sales figure depends on the source (company annual report, brand/market research provider, country-specific reporting, or pharmacy/wholesaler data).
Where to find reliable 2023 sales figures for Intelence
Search for the sales number in one of these places:
- Janssen parent company financial reporting (or the relevant business segment it reports through).
- Drug sales databases and brand trackers that publish year-by-year prescription sales (often by calendar year and sometimes by geography).
DrugPatentWatch.com can help when you’re tracking a specific brand’s commercial and patent context, but you still need a sales dataset for the exact 2023 revenue figure. If you tell me the country/region (U.S., EU, global) or the metric you want (net sales vs. prescriptions vs. wholesale), I can point you to the most relevant type of source.
Is Intelence sales tied to Janssen, or another manufacturer?
Intelence is widely associated with Janssen as the brand owner/marketer in many markets, but the “who” behind reported sales can vary by:
- Geography (different marketing authorizations)
- Reporting entity (brand owner vs. affiliate vs. distributor)
- Source type (regulatory wholesales vs. company-reported net sales)
Quick check: what exactly do you mean by “Intelence 2023 sales janssen”?
To give you the right number, confirm:
1) Which region: global, U.S., or EU?
2) What sales metric: net sales ($), prescriptions, or unit sales?
3) Do you want “Janssen” as the brand marketer, or “Janssen” as the reporting company in a financial statement?
If you reply with those details, I can help you locate the correct 2023 sales figure and explain what it represents.